leukemia

Key Takeaways: A unit of AbbVie has sued BeiGene for alleged patent infringement involving one of the Chinese company’s core products, Brukinsa The lawsuit comes amid rapidly growing sales for Brukinsa, which is used to treat blood cancer, even as sales for AbbVie’s competing product...

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed-lineage leukemia rearranged (MLLr) relapsed/refractory acute leukemias. The data were...

The FDA has signed off Biomea Fusion Inc's (NASDAQ: BMEA) Investigational New Drug application to begin a Phase 1 trial of BMF-219, a selective irreversible menin inhibitor. The trial will include adult patients with relapsed or refractory acute leukemia, including those with an...

Aprea Therapeutics Inc (NASDAQ: APRE) has announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the pre-specified primary efficacy endpoint of complete remission (CR) rate. The trial is assessing eprenetapopt with venetoclax and...

A combination of Johnson & Johnson’s (NYSE: JNJ) Imbruvica and AbbVie Inc (NYSE: ABBV) - Roche Holding AG’s (OTC: RHHBY) Venclexta/Venclyxto (venetoclax) slashed the risk of cancer progression or death by 78.4% compared with a cocktail of...

Aptose Biosciences Inc (NASDAQ: APTO) highlighted data from its luxeptinib currently in two Phase 1 a/b trials - one in relapsed or refractory acute myeloid leukemia (AML) and another in relapsed or refractory B cell malignancies. In Relapsed or Refractory AML or High-Risk MDS trial...

BeiGene Ltd (NASDAQ: BGNE) revealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukinsa (zanubrutinib) to Johnson & Johnson’s (NYSE: JNJ) Imbruvica (ibrutinib) for relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small...

Genentech, a unit of Roche Holdings AG (OTC: RHHBY), and its collaborating partner AbbVie Inc (NYSE: ABBV) have announced long-term follow-up data from two Phase 3 trials of Venclexta (venetoclax) in chronic lymphocytic leukemia (CLL). A post-hoc analysis from a Phase...

Mustang Bio Inc (NASDAQ: MBIO) has updated interim data from the ongoing Phase 1/2 trial evaluating MB-106 for high-risk B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL). The data were presented at the European Hematology Association 2021 Virtual Congress...

AbbVie Inc (NYSE: ABBV) has announced new data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating Imbruvica (ibrutinib) combined with Venclexta/Venclyxto (venetoclax) for untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Data were presented at...

Aptevo Therapeutics Inc (NASDAQ: APVO) has announced positive results from Phase 1 dose-escalation trial evaluating lead ADAPTIR candidate, APVO436, for acute myeloid leukemia and myelodysplastic syndromes (AML/MDS). The study met its primary endpoint of identification of an active...

Curis Inc (NASDAQ: CRIS) stock gained momentum yesterday in reaction to updated data from its Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Four objective responses were recorded with signs of hematologic...

Syndax Pharmaceuticals Inc (NASDAQ: SNDX), in its Q1 earnings, also announced new data from the ongoing Phase 1 dose-escalation portion of the Phase 1/2 AUGMENT-101 trial evaluating SNDX-5613 in patients with MLLr and NPM1c mutant relapsed/refractory (R/R) acute leukemias...

European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Roche Holdings AG’s (OTCMKTS: RHHBY) Enspryng, AbbVie Inc’s (NYSE: ABBV) Venclyxto (venetoclax), and Bristol-Myers Squibb...

Verastem Inc (NASDAQ: VSTM) shares gained 20 percent Monday morning and traded above the $7 per share mark for the first time since 2015 in reaction to an encouraging presentation delivered over the weekend. What Happened Versatem presented encouraging results from its lead candidate...